Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
- Written by PR Newswire
SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter proof-of-concept (POC) study of...